166 related articles for article (PubMed ID: 14974858)
21. Amifostine as a protector against cisplatin-induced toxicity in nude mice.
Johnsson A; Wennerberg J
Acta Oncol; 1999; 38(2):247-53. PubMed ID: 10227448
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
23. A clinically derived guinea pig dosing model of cisplatin ototoxicity.
Stanford JK; Bosworth NA; Morgan DS; Chen T; Spankovich C
Hear Res; 2021 May; 404():108202. PubMed ID: 33621791
[TBL] [Abstract][Full Text] [Related]
24. Is intratympanic injection of erdosteine protective against cisplatin-induced ototoxicity?
Saliba I; El Fata F
Neurotox Res; 2012 Apr; 21(3):302-8. PubMed ID: 21989624
[TBL] [Abstract][Full Text] [Related]
25. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL; Oster W
Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
[TBL] [Abstract][Full Text] [Related]
26. Attenuation of cisplatin ototoxicity by otoprotective effects of nanoencapsulated curcumin and dexamethasone in a guinea pig model.
Salehi P; Akinpelu OV; Waissbluth S; Peleva E; Meehan B; Rak J; Daniel SJ
Otol Neurotol; 2014 Aug; 35(7):1131-9. PubMed ID: 24841915
[TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Ramnath N; LoRusso P; Simon M; Martino S
Am J Clin Oncol; 1997 Aug; 20(4):368-72. PubMed ID: 9256891
[TBL] [Abstract][Full Text] [Related]
28. Protective role of resveratrol against cisplatin induced ototoxicity in guinea pigs.
Yumusakhuylu AC; Yazici M; Sari M; Binnetoglu A; Kosemihal E; Akdas F; Sirvanci S; Yuksel M; Uneri C; Tutkun A
Int J Pediatr Otorhinolaryngol; 2012 Mar; 76(3):404-8. PubMed ID: 22261612
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
[TBL] [Abstract][Full Text] [Related]
30. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.
Small W;
Semin Oncol; 2003 Dec; 30(6 Suppl 18):68-71. PubMed ID: 14727243
[TBL] [Abstract][Full Text] [Related]
31. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig.
Ekborn A; Lindberg A; Laurell G; Wallin I; Eksborg S; Ehrsson H
Cancer Chemother Pharmacol; 2003 Jan; 51(1):36-42. PubMed ID: 12497204
[TBL] [Abstract][Full Text] [Related]
32. Dexamethasone loaded nanoparticles exert protective effects against Cisplatin-induced hearing loss by systemic administration.
Sun C; Wang X; Chen D; Lin X; Yu D; Wu H
Neurosci Lett; 2016 Apr; 619():142-8. PubMed ID: 26971701
[TBL] [Abstract][Full Text] [Related]
33. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect.
Bielefeld EC; Tanaka C; Chen GD; Coling D; Li M; Henderson D; Fetoni AR
Anticancer Drugs; 2013 Jan; 24(1):43-51. PubMed ID: 22828384
[TBL] [Abstract][Full Text] [Related]
34. Systemic co-treatment with alpha-melanocyte stimulating hormone delays hearing loss caused by local cisplatin administration in guinea pigs.
Wolters FL; Klis SF; de Groot JC; Hamers FP; Prieskorn DM; Miller JM; Smoorenburg GF
Hear Res; 2003 May; 179(1-2):53-61. PubMed ID: 12742238
[TBL] [Abstract][Full Text] [Related]
35. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
36. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
Peters GJ; van der Vijgh WJ
Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093
[TBL] [Abstract][Full Text] [Related]
37. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
38. Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model.
Campbell KC; Larsen DL; Meech RP; Rybak LP; Hughes LF
J Am Acad Audiol; 2003 Apr; 14(3):124-33. PubMed ID: 12859137
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents.
Schweitzer VG
Laryngoscope; 1993 Apr; 103(4 Pt 2):1-52. PubMed ID: 8464301
[TBL] [Abstract][Full Text] [Related]
40. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Moore DH; Donnelly J; McGuire WP; Almadrones L; Cella DF; Herzog TJ; Waggoner SE;
J Clin Oncol; 2003 Nov; 21(22):4207-13. PubMed ID: 14615449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
